Can genes modify stroke outcome and by what mechanisms?

Stroke

Volumn 43, Issue 1, 2012, Pages 286-291

  Simon, Roger P ^a   Meller, Robert ^a   Zhou, An ^a   Henshall, David ^b  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

genes; genome; polycomb; preconditioning; proteome; tolerance

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE; HEAT SHOCK PROTEIN; HYPOXIA INDUCIBLE FACTOR; MICRORNA; POLYCOMB GROUP PROTEIN; PROTEIN BCL 2; PROTEIN KINASE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CALCIUM SIGNALING; GENE; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; GENOMICS; HUMAN; ISCHEMIC PRECONDITIONING; MICROARRAY ANALYSIS; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; STROKE;

GENOMICS; HUMANS; STROKE;

EID: 84855345846     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.622225     Document Type: Article

References (62)

1. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477. (Pubitemid 43358067)
2. Sandu N, Cornelius J, Filis A, Arasho B, Perez-Pinzon M, Schaller B. Ischemic tolerance in stroke treatment. Expert Rev Cardiovasc Ther. 2009;7:1255-1261.
3. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci. 2006;7:437-448. (Pubitemid 44012284)
4. Dirnagl U, Becker K, Meisel A. Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol. 2009;8:398-412.
5. Durukan A, Tatlisumak T. Preconditioning-induced ischemic tolerance: a window into endogenous gearing for cerebroprotection. Exp Transl Stroke Med. 2010;2:2-10.
6. Hickey EJ, You X, Kaimaktchiev V, Stenzel-Poore M, Ungerleider RM. Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2007;133:1588-1596. (Pubitemid 46802584)
7. Bahjat FR, Williams-Karnesky RL, Kohama SG, West GA, Doyle KP, Spector MD, et al. Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke. J Cereb Blood Flow Metab. 2011;31: 1229-1242.
8. Schaller B. Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance. Neurosci Lett. 2005;377:206-211. (Pubitemid 40332357)
9. Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD, et al. Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain? Stroke. 1999;30:1851-1854. (Pubitemid 29411826)
10. Wegener S, Gottschalk B, Jovanovic V, Knab R, Fiebach JB, Schellinger PD, et al. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke. 2004;35:616-621. (Pubitemid 38280829)
11. Moncayo J, de Freitas GR, Bogousslavsky J, Altieri M, van Melle G. Do transient ischemic attacks have a neuroprotective effect? Neurology. 2000;54:2089-2094. (Pubitemid 30397207)
12. Keep RF, Wang MM, Xiang J, Hua Y, Xi G. Is There A Place For Cerebral Preconditioning In The Clinic? Transl Stroke Res. 2010;1:4-18.
13. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke. 2009;40:e331-e339.
14. Cheung EC, Joza N, Steenaart NA, McClellan KA, Neuspiel M, McNamara S, et al. Dissociating the dual roles of apoptosis-inducing factor in maintaining mitochondrial structure and apoptosis. Embo J. 2006;25:4061-4073. (Pubitemid 44338747)
15. Gao Y, Liang W, Hu X, Zhang W, Stetler RA, Vosler P, et al. Neuroprotection against hypoxic-ischemic brain injury by inhibiting the apoptotic protease activating factor-1 pathway. Stroke. 2010;41:166-172.
16. Tobaben S, Grohm J, Seiler A, Conrad M, Plesnila N, Culmsee C. Bid-mediated mitochondrial damage is a key mechanism in glutamateinduced oxidative stress and AIF-dependent cell death in immortalized HT-22 hippocampal neurons. Cell Death Differ. 2011;18:282-292.
17. Zhan X, Ander BP, Liao IH, Hansen JE, Kim C, Clements D, et al. Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats. Stroke. 2010;41:538-543.
18. Tsuchiya D, Hong S, Matsumori Y, Kayama T, Swanson RA, Dillman WH, et al. Overexpression of rat heat shock protein 70 reduces neuronal injury after transient focal ischemia, transient global ischemia, or kainic acid-induced seizures. Neurosurgery. 2003;53:1179-1187; discussion 1187-1188.
19. Marsh BJ, Stevens SL, Hunter B, Stenzel-Poore MP. Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia. Stroke. 2009;40:S34-S37.
20. Maysami S, Lan JQ, Minami M, Simon RP. Proliferating progenitor cells: a required cellular element for induction of ischemic tolerance in the brain. J Cereb Blood Flow Metab. 2008;28:1104-1113. (Pubitemid 351733354)
21. Bakondi B, Shimada IS, Perry A, Munoz JR, Ylostalo J, Howard AB, et al. CD133 identifies a human bone marrow stem/progenitor cell subpopulation with a repertoire of secreted factors that protect against stroke. Mol Ther. 2009;17:1938-1947.
22. Stenzel-Poore MP, Stevens SL, Xiong Z, Lessov NS, Harrington CA, Mori M, et al. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet. 2003;362:1028-1037. (Pubitemid 37186880)
23. Storey KB. Biochemistry of natural freeze tolerance in animals: molecular adaptations and applications to cryopreservation. Biochem Cell Biol. 1990;68:687-698. (Pubitemid 20292755)
24. Hochachka PW, Buck LT, Doll CJ, Land SC. Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA. 1996;93:9493-9498. (Pubitemid 26296636)
25. Hatazaki S, Bellver-Estelles C, Jimenez-Mateos EM, Meller R, Bonner C, Murphy N, et al. Microarray profile of seizure damage-refractory hippocampal CA3 in a mouse model of epileptic preconditioning. Neuroscience. 2007;150:467-477. (Pubitemid 350198718)
26. Jimenez-Mateos EM, Hatazaki S, Johnson MB, Bellver-Estelles C, Mouri G, Bonner C, et al. Hippocampal transcriptome after status epilepticus in mice rendered seizure damage-tolerant by epileptic preconditioning features suppressed calcium and neuronal excitability pathways. Neurobiol Dis. 2008;32:442-453.
27. Ploski JE, Newton SS, Duman RS. Electroconvulsive seizure-induced gene expression profile of the hippocampus dentate gyrus granule cell layer. J Neurochem. 2006;99:1122-1132. (Pubitemid 44655278)
28. Borges K, Shaw R, Dingledine R. Gene expression changes after seizure preconditioning in the three major hippocampal cell layers. Neurobiol Dis. 2007;26:66-77. (Pubitemid 46436487)
29. Hunsberger JG, Bennett AH, Selvanayagam E, Duman RS, Newton SS. Gene profiling the response to kainic acid induced seizures. Brain Res Mol Brain Res. 2005;141:95-112. (Pubitemid 41566033)
30. Gorter JA, van Vliet EA, Aronica E, Breit T, Rauwerda H, Lopes da Silva FH, et al. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci. 2006;26: 11083-11110. (Pubitemid 44772198)
31. Lukasiuk K, Kontula L, Pitkänen A. cDNA profiling of epileptogenesis in the rat brain. Eur J Neurosci. 2003;17:271-279. (Pubitemid 36459506)
32. Stenzel-Poore MP, Stevens SL, King JS, Simon RP. Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis. Stroke. 2007;38:680-685. (Pubitemid 46184241)
33. Plamondon H, Blondeau N, Heurteaux C, Lazdunski M. Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels. J Cereb Blood Flow Metab. 1999;19:1296-1308. (Pubitemid 30013620)
34. Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, et al. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci. 2009;29:9839-9849.
35. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, et al. Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci. 2011;31:8456-8463.
36. Lusardi TA, Farr CD, Faulkner CL, Pignataro G, Yang T, Lan J, et al. Ischemic preconditioning regulates expression of microRNAs and a predicted target, MeCP2, in mouse cortex. J Cereb Blood Flow Metab. 2010;30:744-756.
37. Ambros V. The functions of animal microRNAs. Nature. 2004;431: 350-355. (Pubitemid 39265675)
38. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
39. Gebauer F, Hentze MW. Molecular mechanisms of translational control. Nat Rev Mol Cell Biol. 2004;5:827-835. (Pubitemid 39336276)
40. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007;17: 118-126. (Pubitemid 46357525)
41. Shyu AB, Wilkinson MF, van Hoof A. Messenger RNA regulation: to translate or to degrade. Embo J. 2008;27:471-481. (Pubitemid 351225677)
42. Kai ZS, Pasquinelli AE. MicroRNA assassins: factors that regulate the disappearance of miRNAs. Nat Struct Mol Biol. 2010;17:5-10.
43. Saugstad JA. MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration. J Cereb Blood Flow Metab. 2010;30:1564-1576.
44. Stapels M, Piper C, Yang T, Li M, Stowell C, Xiong ZG, et al. Polycomb group proteins as epigenetic mediators of neuroprotection in ischemic tolerance. Sci Signal. 2010;3:ra15.
45. Stowell C, Wang L, Arbogast B, Lan JQ, Cioffi GA, Burgoyne CF, et al. Retinal proteomic changes under different ischemic conditions-implication of an epigenetic regulatory mechanism. Int J Physiol Pathophysiol Pharmacol. 2010;2:148-160.
46. Vogel T, Stoykova A, Gruss P. Differential expression of polycomb repression complex 1 (PRC1) members in the developing mouse brain reveals multiple complexes. Dev Dyn. 2006;235:2574-2585. (Pubitemid 44325270)
47. Grimaud C, Nègre N, Cavalli G. From genetics to epigenetics: the tale of Polycomb group and trithorax group genes. Chromosome Res. 2006;14: 363-375.
48. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20:1123-1136.
49. Köhler C, Villar CB. Programming of gene expression by Polycomb group proteins. Trends Cell Biol. 2008;18:236-243.
50. Otte AP, Kwaks TH. Gene repression by Polycomb group protein complexes: a distinct complex for every occasion? Curr Opin Genet Dev. 2003;13:448-454. (Pubitemid 37204919)
51. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846-856. (Pubitemid 44629896)
52. Zukin RS. Eradicating the mediators of neuronal death with a fine-tooth comb. Sci Signal. 2010;3:pe20.
53. Bantignies F, Cavalli G. Cellular memory and dynamic regulation of polycomb group proteins. Curr Opin Cell Biol. 2006;18:275-283.
54. Tolhuis B, de Wit E, Muijrers I, Teunissen H, Talhout W, van Steensel B, et al. Genome-wide profiling of PRC1 and PRC2 Polycomb chromatin binding in Drosophila melanogaster. Nat Genet. 2006;38:694-699. (Pubitemid 43927313)
55. Kerppola TK. Polycomb group complexes-many combinations, many functions. Trends Cell Biol. 2009;19:692-704.
56. Schuettengruber B, Cavalli G. Recruitment of polycomb group complexes and their role in the dynamic regulation of cell fate choice. Development. 2009;136:3531-3542.
57. Takada Y, Isono K, Shinga J, Turner JM, Kitamura H, Ohara O, et al. Mammalian Polycomb Scmh1 mediates exclusion of Polycomb complexes from the XY body in the pachytene spermatocytes. Development. 2007;134:579-590. (Pubitemid 46332494)
58. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell. 2005;20:845-854. (Pubitemid 41814874)
59. Friedman JM, Jones PA, Liang G. The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle. 2009;8:2313-2314.
60. Kim DH, Saetrom P, Snøve O, Jr., Rossi JJ. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci USA. 2008;105:16230-16235.
61. Mills AA. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer. 2010;10:669-682.
62. Yoon KA, Gil HJ, Han J, Park J, Lee JS. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J Thorac Oncol. 2010;5:10-16.